Anti-CTLA-4 therapy has been approved for several cancers [43], extending survival of glioma-bearing mice [59], and in combination with anti-PD-1 therapy, shown eradication of tumors in a majority of mice [60]. Here, PDCD1 is linked to central nervous system cancer.